MMS19

Across TCGA pan-cancer cohorts, MMS19 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MMS19 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MMS19 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MMS19 expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

CCRCC, COAD, and LUAD are the cancer types where MMS19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.744	0.945	.011	22	view →
COAD	DFS	Median	All	0.916	1.000	.010	18	view →
LUAD	DFS	Median	II,III,IV	0.217	0.736	.007	18	view →
PDAC	DFS	Quartile	All	0.222	0.469	.003	12	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.472	.018	8	view →
HNSC	OS	Median	II,III,IV	0.992	0.933	.024	7	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.849	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MMS19–CCRCC (OS)

Open the CCRCC breakdown →